CDKI-83 is a potent CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 <1 μM, and is capable of inducing apoptosis in A2780 human ovarian cancer cells as determined by the activated caspase-3, Annexin V/PI double staining and accumulated cells at the sub-G1 phase of cellcycle. The research results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent. References: Liu X, Lam F, Shi S, Fischer PM, Wang S. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. 2012 Jun;30(3):889-97. doi: 10.1007/s10637-011-9641-5. Epub 2011 Feb 18. PubMed PMID: 21331744.

纯度：≥98%

CAS：1189558-88-0